2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 457

Biologic Disease-Modifying Anti-Rheumatic Drugs and the Risk of Non-Vertebral Osteoporotic Fractures in Patients with Rheumatoid Arthritis Aged 50 Years and Over
Abstract Number: 2638

Biologic Switching Among Patients with Rheumatoid Arthritis in the United States, 2004-2011
Abstract Number: 1801

Biological Roles of C5orf30 in Rheumatoid Arthritis
Abstract Number: 1642

Biologics and Mortality Risk in Rheumatoid Arthritis – Results of a Population Based Study
Abstract Number: 1923

Biologics in Relapsing Polychondritis: A Single Center Case-Series
Abstract Number: 1709

Biomarkers of Atherosclerosis Are Associated with Progression of Non-Cardiovascular Damage in Patients with SLE
Abstract Number: 2498

Biomarkers of Mitochondrial Dysfunction Correlate with Disease Activity in SLE
Abstract Number: 719

Biomarkers of Pulmonary Hypertension in Patients with Scleroderma: A Case-Control Study
Abstract Number: 790

Biomechanical Function Agrees with Clinical Implications of Foot Disorders in a Population-Based Study
Abstract Number: 1512

Bleomycin Delivery by Osmotic Pump: A Superior Model for Human ILD
Abstract Number: L6

Blisibimod, an Inhibitor of B Cell Activating Factor, in Patients with Moderate-to-Severe Systemic Lupus Erythematosus
Abstract Number: 332

Blockade of CTGF Restores Aberrant Ostoclastgenesis in Collagen Induced Arthritis (CIA) Mice Through Inhibition of Th-17 Differentiation
Abstract Number: 2681

Blocking the Serum Protease Inhibitor Activity of Plasminogen Activator Inhibitor-1 Protects Mice From Development of Glomerulonephritis in a Model of Lupus Nephritis
Abstract Number: 2392

Blood Vessel Instability and Oxidative Damage in Giant Cell Arteritis
Abstract Number: 312

Blood-Based Biomarkers of Neurocognitive Dysfunction in Childhood-Onset Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].